Literature DB >> 22778377

Nocardiosis in a patient with rheumatoid arthritis treated with rituximab and a summary of reported cases.

C S Ngiu1, M S Mohamed Said, P Periyasamy, S F Low.   

Abstract

Rituximab is a B-cell-depleting monoclonal anti-CD20 antibody. It is widely used in haematology and rheumatology. However, usage of rituximab in immunosupressed patient has been associated with various opportunistic infections. The authors reported a case of refractory rheumatoid arthritis treated with rituximab, which later presented with non-resolving pneumonia with pulmonary nodule. Percutaneous computer tomogram guided lung biopsy was arranged to confirm the suspicion of tuberculosis, but did not yield conclusive results. Later, she presented left-chest abscess and underwent incision and drainage. The pus culture and sensitivity confirmed pulmonary nocardiosis with chest wall dissemination. She was treated with 2-week course of trimethoprim sulfamethoxazole and responded. The authors also reviewed published cases of nocardiosis post-rituximab.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22778377      PMCID: PMC3029947          DOI: 10.1136/bcr.11.2009.2421

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Authors:  Stanley B Cohen; Paul Emery; Maria W Greenwald; Maxime Dougados; Richard A Furie; Mark C Genovese; Edward C Keystone; James E Loveless; Gerd-Rüdiger Burmester; Matthew W Cravets; Eva W Hessey; Timothy Shaw; Mark C Totoritis
Journal:  Arthritis Rheum       Date:  2006-09

2.  Nocardia veterana bloodstream infection in a patient with cancer and a summary of reported cases.

Authors:  Shoaib R Ansari; Amar Safdar; Xiang Y Han; Susan O'Brien
Journal:  Int J Infect Dis       Date:  2006-07-28       Impact factor: 3.623

3.  Systemic nocardiosis in a case of rheumatoid arthritis treated with tumor necrosis factor blockers.

Authors:  Daniel Wendling; Muhsen Murad; Sandra Mathieu; Eric Berger; Lucien Rumbach
Journal:  J Rheumatol       Date:  2008-03       Impact factor: 4.666

4.  Cerebral nocardiosis in a patient with NHL treated with rituximab.

Authors:  Madappa N Kundranda; Timothy P Spiro; Alaa Muslimani; K V Gopalakrishna; Mark J Melaragno; Hamed A Daw
Journal:  Am J Hematol       Date:  2007-11       Impact factor: 10.047

Review 5.  A case series and focused review of nocardiosis: clinical and microbiologic aspects.

Authors:  Edith R Lederman; Nancy F Crum
Journal:  Medicine (Baltimore)       Date:  2004-09       Impact factor: 1.889

Review 6.  Pulmonary nocardiosis: risk factors, clinical features, diagnosis and prognosis.

Authors:  Raquel Martínez; Soledad Reyes; Rosario Menéndez
Journal:  Curr Opin Pulm Med       Date:  2008-05       Impact factor: 3.155

7.  Nocardia arthritidis sp. nov., a new pathogen isolated from a patient with rheumatoid arthritis in Japan.

Authors:  Akiko Kageyama; Kimiaki Torikoe; Masahiro Iwamoto; Jun-Ichi Masuyama; Yasuhiro Shibuya; Hitoaki Okazaki; Katsukiyo Yazawa; Seiji Minota; Reiner M Kroppenstedt; Yuzuru Mikami
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

8.  Nocardiosis in a renal transplant recipient following rituximab preconditioning.

Authors:  Tanya R Flohr; Costi D Sifri; Kenneth L Brayman; Klaus D Hagspiel; Robert G Sawyer; Timothy L Pruett; Hugo J R Bonatti
Journal:  Ups J Med Sci       Date:  2009       Impact factor: 2.384

Review 9.  Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.

Authors:  C Salliot; M Dougados; L Gossec
Journal:  Ann Rheum Dis       Date:  2008-01-18       Impact factor: 19.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.